5 completed, 4 terminated, 3 unknown, 2 withdrawn. 8 Phase 3, 4 Phase 4, 3 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 3, Unknown 2, Enrolling by invitation 1, Recruiting 1, Terminated 1 |
| Phase 4 | 4 | Terminated 3, Withdrawn 1 |
| Phase 2 | 3 | Completed 3 |
| Not applicable | 1 | Unknown 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Sulodexide: new trials by email Literature Review of Sulodexide trials Research Report on Sulodexide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sulodexide in Controlling the Recurrence of Psoriasis Sulodexide, Placebo - Psoriasis (PsO), Randomised Controlled Trial | Phase 3 | Enrolling by invitation | Xijing Hospital | 160 | 2025-04-20 | 2025-05-21 |
| Endothelial Protection in Post COVID-19 Patients With Sulodexide Sulodexide - Post COVID-19, Endothelial Dysfunction | Phase 3 | Completed | Centro Medico del Noroeste | 206 | 2023-06-01 | 2024-08-09 |
| The Study of Reducing Adverse Effects After Radiofrequency Ablation Combined With Sclerotherapy Sulodexide - Vascular Diseases, Peripheral, Venous Insufficiency of Leg | Not applicable | Unknown | Chengdu University of Traditional Chinese Medicine | 120 | 2023-02-01 | 2023-01-03 |
| Endothelial Protection in Convalescent COVID-19 Patients Sulodexide - Endothelial Dysfunction, Inflammation | Phase 4 | Terminated | Pirogov Russian National Research Medical University | 2 | 2022-04-01 | 2025-06-13 |
| Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study) Sulodexide, Sulodexide and placebo, Placebo - Venous Thromboembolism, Anticoagulant | Phase 3 | Recruiting | Arianna Anticoagulazione Foundation | 1455 | 2020-12-21 | 2024-07-31 |
| Suloexide in the Treatment of Early Stages of COVID-19 Sulodexide, Placebo - Covid19 | Phase 2 / Phase 3 | Completed | Clinedem | 243 | 2020-06-05 | 2020-09-09 |
| Endothelial Function Evaluation in Patients With PAOD Treated With Sulodexide + Conventional Treatment (CT) Vs CT Alone Sulodexide, Statin, Antiplatelet Agents - Peripheral Arterial Obstructive Disease | Phase 3 | Unknown | Alfa Wassermann Tunisia | 156 | 2019-01-31 | 2019-12-02 |
| Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2) Linagliptin, Empagliflozin, Telmisartan - Diabetic Nephropathy Type 2 | Phase 4 | Withdrawn | Steno Diabetes Center Copenhagen | 2017-11-15 | 2018-09-14 | |
| Prospective Evaluation of the QoL of Patients With PTS Who Receive Compression Therapy and Sulodexide Sulodexide, Compression therapy - Post-thrombotic Syndrome | Phase 4 | Terminated | Bama GeVe, S.L.U. | 13 | 2015-09-01 | 2017-08-31 |
| Sulodexide Efficacy in Chronic Idiopathic Subjective Tinnitus Sulodexide, Placebo - Tinnitus, Subjective | Phase 2 | Completed | St Joseph University, Beirut, Lebanon | 126 | 2014-08-01 | 2017-09-14 |
| The Efficacy and Safety Study of Sulodexide in Filipino Diabetic Patients With Chronic Kidney Disease Sulodexide, placebo capsules - Chronic Kidney Disease | Phase 3 | Unknown | Corbridge Group Philippines, Inc. | 1508 | 2009-11-01 | 2009-10-30 |
| Diabetic Retinopathy Sulodexide Study sulodexide - Diabetic Retinopathy | Phase 2 | Completed | Ajou University School of Medicine | 127 | 2009-02-01 | 2012-11-06 |
| Sulodexide Treatment in Patients With Dense Deposit Disease Sulodexide - Dense Deposit Disease | Phase 1 | Withdrawn | University of Iowa | 2007-12-01 | 2015-06-11 | |
| Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong sulodexide - Diabetic Nephropathy | Phase 3 | Terminated | Keryx Biopharmaceuticals | 200 | 2007-04-01 | 2017-03-03 |
| Effect of Sulodexide in Early Diabetic Nephropathy Sulodexide, Placebo - Diabetic Nephropathy | Phase 3 | Completed | Keryx Biopharmaceuticals | 1056 | 2005-08-01 | 2018-03-23 |
| Effect of Sulodexide in Overt Diabetic Nephropathy Sulodexide, Placebo - Diabetic Nephropathy | Phase 4 | Terminated | Keryx Biopharmaceuticals | 968 | 2005-08-01 | 2021-03-19 |
Diabetes Mellitus (4) · Diabetic Nephropathies (3) · Albuminuria (2) · COVID-19 (2) · Proteinuria (2) · Thrombosis (2) · Diabetes Mellitus, Type 2 (1) · Diabetic Retinopathy (1) · Glomerulonephritis, Membranoproliferative (1) · Hemorrhage (1) · Inflammation (1) · Kidney Diseases (1) · Microaneurysm (1) · Peripheral Vascular Diseases (1) · Postthrombotic Syndrome (1)
Keryx Biopharmaceuticals (3) · Ajou University School of Medicine (1) · Alfa Wassermann Tunisia (1) · Arianna Anticoagulazione Foundation (1) · Bama GeVe, S.L.U. (1) · Centro Medico del Noroeste (1) · Chengdu University of Traditional Chinese Medicine (1) · Clinedem (1) · Corbridge Group Philippines, Inc. (1) · Pirogov Russian National Research Medical University (1) · St Joseph University, Beirut, Lebanon (1) · Steno Diabetes Center Copenhagen (1) · University of Iowa (1) · Xijing Hospital (1)
Australia (3) · United States (3) · China (2) · Mexico (2) · Netherlands (2) · Denmark (1) · Italy (1) · Lebanon (1) · Philippines (1) · Russia (1) · South Korea (1) · Spain (1) · Tunisia (1)
Itamar Raz, M.D. (2) · Robert C Atkins, M.D. (2) · Alejandro J Gonzalez-Ochoa, MD (1) · Anne Reutens, MD (1) · Corrado Lodigiani, MD,PhD (1) · Edmund J Lewis, M.D. (1) · Edmund J Lewis, MD (1) · Elias Eter, MD (1) · Gang Wang (1) · Ha Kyoung Kim, MD (1) · Imed Frikha, MD (1) · Josep Marinel.lo (1)
PMID 21872376, PMID 25112845, PMID 28341782, PMID 31595056, PMID 31899186, PMID 32365242, PMID 32427307, PMID 32451933, PMID 32888954, PMID 33812489, PMID 33995668, PMID 35244208, PMID 35601055, PMID 36917196
2019 (1)